Meeting
2023 ASCO Annual Meeting
ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.
Authors
Paul Severson
Kinnate Biopharma, San Francisco, CA
Paul Severson , Julia Sytnikova , Adithi Mohan , Nicole Zhang , Elifnur Yay Donderici , Richard Thomas Williams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3049)
DOI
10.1200/JCO.2023.41.16_suppl.3049
Abstract #
3049
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
First Author: Milind M. Javle
Poster
2023 ASCO Genitourinary Cancers Symposium
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
First Author: Benjamin Garmezy
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
First Author: James J. Harding
Poster
2022 ASCO Annual Meeting
Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
First Author: Lipika Goyal